An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

Trial Profile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Chickenpox; Diphtheria; Haemophilus infections; Hepatitis B; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 08 Apr 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 01 Jul 2008 The expected completion date for this trial is now 1 Mar 2008, according to ClinicalTrials.gov.
    • 01 Jul 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top